Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Preferred Stock Liabilities (2020)

Bolt Biotherapeutics (BOLT) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $105.3 million as the latest value for Q4 2020.

  • Quarterly Preferred Stock Liabilities changed N/A to $105.3 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $105.3 million through Dec 2020, changed N/A year-over-year, with the annual reading at $105.3 million for FY2020, N/A changed from the prior year.
  • Preferred Stock Liabilities hit $105.3 million in Q4 2020 for Bolt Biotherapeutics, roughly flat from $105.3 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $105.3 million in Q3 2020 to a low of $41.3 million in Q2 2020.